常见肿瘤维持治疗的成功模式

摘要/Abstract

摘要：维持治疗已成为肿瘤治疗的有效策略，分为持续维持治疗和转换维持治疗，其经典模式为节拍化疗。维持治疗在非小细胞肺癌、乳腺癌、结直肠癌和卵巢癌中的成功应用显示了其潜在价值。

张百红,岳红云. 常见肿瘤维持治疗的成功模式[J]. 国际肿瘤学杂志, 2014, 41(8): 655-658.

Zhang Baihong, Yue Hongyun. Successful patterns of maintenance therapy in human common cancer[J]. Journal of International Oncology, 2014, 41(8): 655-658.

［1］ Gerber DE, Schiller JH. Maintenance chemotherapy for advanced nonsmallcell lung cancer: new life for an old idea［J］. J Clin Oncol, 2013, 31(8): 1009-1020. ［2］ André N, Banavali S, Snihur Y, et al. Has the time come for metronomics in lowincome and middleincome countries?［J］. Lancet Oncol, 2013, 14(6): e239-248. ［3］ Loven D, Hasnis E, Bertolini F, et al. Lowdose metronomicchemotherapy: from past experience to new paradigms in the treatment of cancer［J］. Drug Discov Today, 2013, 18(34): 193-201. ［4］ Granovetter M. Maintenance therapy improves survival of NSCLC patients［J］. Lancet Oncol, 2013, 14(9): e347. ［5］ PazAres L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced nonsquamous nonsmallcell lung cancer (PARAMOUNT): a doubleblind, phase 3, randomised controlled trial［J］. Lancet Oncol, 2012, 13(3): 247-255. ［6］ PazAres LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous nonsmallcell lung cancer［J］. J Clin Oncol, 2013, 31(23): 2895-2902. ［7］ Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase Ⅲ trial of maintenance bevacizumab with or without pemetrexed after firstline induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous nonsmallcell lung cancer: AVAPERL (MO22089)［J］. J Clin Oncol, 2013, 31(24): 3004-3011. ［8］ Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced nonsmallcell lung cancer given maintenance treatment with pemetrexed versus placebo (H3EMCJMEN): results from a randomised, doubleblind, phase 3 study［J］. Lancet Oncol, 2012, 13(3): 292-299. ［9］ Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase Ⅲ study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage ⅢB or Ⅳ nonsquamous nonsmallcell lung cancer［J］. J Clin Oncol, 2013, 31(34): 4349-4357. ［10］ Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (LBLP25) versus placebo after chemoradiotherapy for stage Ⅲ nonsmallcell lung cancer (START): a randomised, doubleblind, phase 3 trial［J］. Lancet Oncol, 2014, 15(1): 5968. ［11］ Park YH, Jung KH, Im SA, et al. Phase Ⅲ, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as firstline chemotherapy: KCSGBR0702［J］. J Clin Oncol, 2013, 31(14): 1732-1739. ［12］ Fedele P, Marino A, Orlando L, et al. Efficacy and safety of lowdose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer［J］. Eur J Cancer, 2012, 48(1): 24-29. ［13］ Fabi A, Russillo M, Ferretti G, et al. Maintenance bevacizumab beyond firstline paclitaxel plus bevacizumab in patients with Her2negative hormone receptorpositive metastatic breast cancer: efficacy in combination with hormonal therapy［J］. BMC Cancer, 2012, 12: 482. ［14］ Pagani O, Gelber S, Colleoni M, et al. Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 1393 and 1493［J］.Breast Cancer Res Treat, 2013, 142(2): 455-459. ［15］ Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial［J］. Lancet Oncol, 2013, 14(1): 29-37. ［16］ Rosati G, Avallone A, Aprile G, et al. XELOX and bevacizumab followed by singleagent bevacizumab as maintenance therapy as firstline treatment in elderly patients with advanced colorectal cancer: the boxe study［J］. Cancer Chemother Pharmacol, 2013, 71(1): 257-264. ［17］ Yalcin S, Uslu R, Dane F, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase Ⅲ 'stop and Go' study resultsa Turkish Oncology Group Trial［J］. Oncology, 2013, 85(6): 328-335. ［18］ Itamochi H, Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer［J］. Int J Clin Oncol, 2012, 17(5): 430-440. ［19］ Barton MK. Small reduction in quality of life seen with bevacizumabmaintenance in patients with ovarian cancer［J］. CA Cancer J Clin, 2013, 63(4): 219-220. ［20］ Vergote IB, Jimeno A, Joly F, et al. Randomized phase Ⅲ study of erlotinib versus observation in patients with no evidence of disease progression after firstline platinbased chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of CancerGynaecological Cancer Group, and Gynecologic Cancer Intergroup Study［J］. J Clin Oncol, 2014, 32(4): 320-326. ［21］ Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer［J］. N Engl J Med, 2012, 366(15): 1382-1392. ［22］ Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib［J］. Onco Targets Ther, 2013, 6: 1197-1206. ［23］ Vergote IB, Chekerov R, Amant F, et al. Randomized, phase Ⅱ, placebocontrolled, doubleblind study with and without enzastaurin in combination with paclitaxel and carboplatin as firstline treatment followed by maintenance treatment in advanced ovarian cancer［J］. J Clin Oncol, 2013, 31(25): 3127-3132. ［24］ Sabbatini P, Harter P, Scambia G, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase Ⅲ trial of the AGO OVAR, COGI, GINECO, and GEICOthe MIMOSA study［J］. J Clin Oncol, 2013, 31(12): 1554-1561. ［25］ Palacio S, LoaizaBonilla A, Kittaneh M, et al. Successful use of trastuzumab with anthracyclinebased chemotherapy followed by trastuzumab maintenance in patients with advanced HER2positive gastric cancer［J］. Anticancer Res, 2014, 34(1): 301-306. ［26］ Reni M, Cereda S, Milella M, et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase Ⅱ randomised trial［J］. Eur J Cancer, 2013, 49(17): 3609-3615.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[14]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[15]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.

Successful patterns of maintenance therapy in human common cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价